Vivos Therapeutics, Inc.VVOSEarnings & Financial Report
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
Revenue
$6.8M
Gross Profit
$3.9M
Operating Profit
$-4.7M
Net Profit
$-5.4M
Gross Margin
58.0%
Operating Margin
-69.8%
Net Margin
-79.6%
YoY Growth
75.7%
EPS
$-0.49
Vivos Therapeutics, Inc. Q3 FY2025 Financial Summary
Vivos Therapeutics, Inc. reported revenue of $6.8M (up 75.7% YoY) for Q3 FY2025, with a net profit of $-5.4M (down 106.4% YoY) (-79.6% margin). Cost of goods sold was $2.8M, operating expenses totaled $8.7M.
Key Financial Metrics
| Total Revenue | $6.8M |
|---|---|
| Net Profit | $-5.4M |
| Gross Margin | 58.0% |
| Operating Margin | -69.8% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Vivos Therapeutics, Inc. Q3 FY2025 revenue of $6.8M breaks down across 2 segments, led by Services at $4.6M (67.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Services | $4.6M | 67.6% |
| The Sleep Center Of Nevada | $2.2M | 32.4% |
Vivos Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Vivos Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Services and The Sleep Center Of Nevada) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Services | $3.2M | $4.6M | — | — |
| The Sleep Center Of Nevada | — | $2.2M | — | — |
Vivos Therapeutics, Inc. Annual Revenue by Year
Vivos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $17.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $17.4M |
| 2024 | $15.0M |
| 2023 | $13.8M |
| 2022 | $16.0M |
Vivos Therapeutics, Inc. Quarterly Revenue & Net Profit History
Vivos Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.8M | +3.4% | $-6.9M | -180.3% |
| Q3 FY2025 | $6.8M | +75.7% | $-5.4M | -79.6% |
| Q2 FY2025 | $3.8M | -5.8% | $-5.0M | -131.2% |
| Q1 FY2025 | $3.0M | -11.8% | $-3.9M | -128.1% |
| Q4 FY2024 | $3.7M | +13.9% | $-2.8M | -76.4% |
| Q3 FY2024 | $3.9M | +16.9% | $-2.6M | -67.8% |
| Q2 FY2024 | $4.1M | +19.4% | $-1.9M | -47.6% |
| Q1 FY2024 | $3.4M | -11.4% | $-3.8M | -110.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $4.1M | $3.9M | $3.7M | $3.0M | $3.8M | $6.8M | $3.8M |
| YoY Growth | -11.4% | 19.4% | 16.9% | 13.9% | -11.8% | -5.8% | 75.7% | 3.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.8M | $15.8M | $15.3M | $15.3M | $11.3M | $26.0M | $25.6M | $25.2M |
| Liabilities | $11.2M | $9.5M | $7.7M | $7.3M | $6.9M | $21.4M | $23.1M | $26.7M |
| Equity | $582000 | $6.3M | $7.7M | $8.0M | $4.4M | $4.6M | $2.5M | $-1.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.5M | $-3.0M | $-4.2M | $-2.9M | $-3.8M | $-3.5M | $-4.2M | $-3.8M |